SUTENT Clinical Trial Results
SUTENT was studied in a clinical trial involving 615 adult patients who were at high risk of RCC coming back after kidney cancer surgery. For approximately 1 year after kidney cancer surgery, 309 patients took SUTENT, while 306 took a placebo, or sugar pill.
What is adjuvant therapy?
Adjuvant therapy is an additional treatment taken after your primary treatment, such as surgery. The goal of adjuvant therapy is to help reduce the risk of recurrence. As you read on, you’ll find out more about SUTENT, the only FDA-approved adjuvant therapy for adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back after having kidney surgery.
How kidney cancer can come back after surgery
About kidney cancer surgery
If you’ve had or are considering kidney cancer surgery, it’s important to understand the role it plays in your treatment. Surgery is often the standard approach to treat kidney cancer. The goal of kidney cancer surgery is to physically remove all of
the cancer by taking out the tumor.
Recommended dosage for adults with kidney cancer that has not spread (localized) and who are at high risk of renal cell carcinoma (RCC) coming back after having kidney cancer surgery
If you are prescribed SUTENT as adjuvant therapy, the recommended dose is 50 mg taken orally once a day.
SUTENT may not work the same way in every person. SUTENT may help slow the spread of cancer.
In clinical trials, SUTENT was shown to help slow the spread of cancer. SUTENT may also help shrink some tumors. SUTENT is not a cure, and not all patients will experience the same results.
SUTENT has been proven effective in the treatment of GIST in certain patients†
A clinical trial proved that SUTENT is an effective treatment for certain patients with GIST.†
SUTENT has been proven effective in the treatment of advanced pNET in certain patients
A clinical trial proved that SUTENT is an effective treatment for advanced pNET.
Nearly twice the time without progression
Patients treated with SUTENT lived nearly twice the number of months without progression compared with those on placebo.
General cancer resources: